NEW YORK (GenomeWeb) – Lucence Diagnostics said today that it has partnered with Myanmar-based firm Mascots Medical and Laboratory Centre to distribute Lucence's blood-based cancer diagnostic tests and treatment in Myanmar.
Under the terms of the agreement, Mascots will distribute Lucence's blood tests, which detect DNA fragments shed by a tumor into the blood to identify cancer-driving mutations. The assays target a variety of cancers, including breast, colon, lung, and pancreatic cancers.
Financial and other terms of the agreement were not disclosed.
"Through this partnership with Lucence, we can provide simple blood tests to help our people detect cancer as early as possible, understand their risk of cancer, and provide them with a better choice of cancer treatment," Mascots Director Thynn Myo Myo Aye said in a statement.
The distribution deal in Myanmar follows similar distribution agreements covering Lucence's cancer detection assays in Asia during the last few months, including agreements in Thailand, Singapore, and the Philippines.